CTXR Logo

Citius Pharmaceuticals, Inc. (CTXR) 

NASDAQ
Market Cap
$21.86M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
632 of 963
Rank in Industry
349 of 552

Largest Insider Buys in Sector

CTXR Stock Price History Chart

CTXR Stock Performance

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Insider Activity of Citius Pharmaceuticals, Inc.

Over the last 12 months, insiders at Citius Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Citius Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Citius Pharmaceuticals, Inc. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,234,700 shares for transaction amount of $2M was made by Mazur Leonard L (Executive Chairman) on 2019‑09‑27.

List of Insider Buy and Sell Transactions, Citius Pharmaceuticals, Inc.

2019-09-27PurchaseExecutive Chairman
2.23M
13.7793%
$0.90$2M+20.83%
2019-09-27PurchasePresident and CEO
558,597
3.4443%
$0.90$500,000+20.83%
2019-04-03PurchaseExecutive Chairman
1.17M
6.2256%
$1.54$1.8M-23.77%
2019-04-03PurchasePresident and CEO
129,450
0.6917%
$1.54$200,000-23.77%
2018-08-13PurchaseExecutive Chairman
3.14M
27.0206%
$1.27$4M-14.12%
2018-08-13PurchasePresident and CEO
784,314
6.7551%
$1.27$1M-14.12%
2018-03-29PurchaseExecutive Chairman
167,504
1.6135%
$2.98$499,999-51.29%
2018-03-28PurchasePresident and CEO
2,915
0.0277%
$3.09$9,007-53.54%
2017-12-19PurchaseExecutive Chairman
213,106
2.6762%
$4.69$999,467-41.71%
2017-08-24PurchaseExecutive Chairman
11,000
0.2205%
$2.68$29,480+15.56%
2017-08-08PurchaseExecutive Chairman
421,400
11.6995%
$4.13$1.74M+4.00%
2016-03-30Purchasedirector
10M
6.4441%
$0.60$6M-74.93%

Insider Historical Profitability

<0.0001%
Mazur Leonard LExecutive Chairman
10255343
132.7168%
$2.8380<0.0001%
HOLUBIAK MYRON ZPresident and CEO
1992243
25.7821%
$2.8340<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$7.83M4.838.73M+3.18%+$241,085.63<0.0001
The Vanguard Group$6.29M3.887.01M+1.52%+$94,116.91<0.0001
Geode Capital Management$2.64M1.632.95M+5.96%+$148,599.28<0.0001
State Street$1.98M1.222.21M+0.1%+$1,976.75<0.0001
Northern Trust$1.01M0.621.12M+7.19%+$67,435.73<0.0001
Advisor Group Holdings Inc$836,681.000.52932,333+<0.01%+$71.79<0.01
Nuveen$434,876.000.27484,6490%+$0<0.0001
Charles Schwab$320,331.000.2356,9940%+$0<0.0001
BNY Mellon$287,460.000.18320,361-6.42%-$19,707.40<0.0001
Hightower Advisors$188,000.000.12209,855+3.37%+$6,124.08<0.0001
Morgan Stanley$171,982.000.11191,667-21.43%-$46,921.39<0.0001
Inspire Advisors$141,258.000.09157,426-13.85%-$22,713.300.04
RhumbLine Advisers$140,686.000.09156,853+4.48%+$6,036.33<0.0001
Wealth Advisory Solutions Llc$135,492.000.08151,000New+$135,492.000.04
UBS$120,748.000.08134,613-2.11%-$2,601.30<0.0001
Arkadios Wealth Advisors$89,730.000.06100,0000%+$00.01
Blair William Co Il$86,320.000.0596,200+5.48%+$4,486.49<0.0001
Barclays$85,000.000.0594,468-44.04%-$66,902.81<0.0001
Deutsche Bank$77,788.000.0586,4310%+$0<0.0001
Goldman Sachs$78,500.000.0587,485-5.48%-$4,551.09<0.0001
Kestra Advisory Services LLC$72,582.000.0580,889+11.69%+$7,596.57<0.01
Chelsea Counsel Co$72,951.000.0581,3000%+$00.04
Jane Street Capital$70,392.000.0478,449-20.51%-$18,164.87<0.0001
New York State Common Retirement Fund$70,000.000.0477,9900%+$0<0.0001
Xtx Topco Ltd$69,636.000.0477,606+510.54%+$58,230.40<0.01
Horst & Graben Wealth Management$67,945.000.0475,7220%+$00.01
American International Group$59,488.000.0466,297+8.53%+$4,676.70<0.0001
LINSCO PRIVATE LEDGER CORP$52,479.000.0358,485+0.21%+$112.16<0.0001
Invesco$50,567.000.0356,355-3.33%-$1,738.96<0.0001
Bank of America$46,819.000.0352,195-71.1%-$115,193.85<0.0001
Wells Fargo$45,620.000.0350,842+22.85%+$8,484.77<0.0001
JPMorgan Chase$45,964.000.0351,224-35.77%-$25,592.29<0.0001
Miller Investment Management Lp$44,865.000.0350,0000%+$00.01
Voya Investment Management LLC$42,971.000.0347,889-7.69%-$3,578.45<0.0001
SG Americas Securities, LLC$37,000.000.0241,020-34.96%-$19,887.27<0.0001
Private Advisor Group$35,892.000.0240,0000%+$0<0.0001
T. Rowe Price$28,000.000.0230,231+7.46%+$1,945.02<0.0001
Tcg Advisory Services Llc$26,919.000.0230,0000%+$0<0.01
Citigroup$22,341.000.0124,898+40.71%+$6,464.16<0.0001
ProShares$21,687.000.0124,169+18.82%+$3,435.79<0.0001
Group One Trading$17,555.000.0119,564-23.58%-$5,417.97<0.0001
Victory Capital Management Inc$17,343.000.0119,328-2.16%-$382.25<0.0001
Fidelity Investments$15,949.000.0117,774-4.09%-$680.17<0.0001
HSBC$13,719.000.0115,289New+$13,719.00<0.0001
Franklin Templeton Investments$12,808.000.0114,2740%+$0<0.0001
Csenge Advisory Group$13,460.000.0115,0000%+$0<0.01
CalSTRS$12,134.000.0113,523-33.15%-$6,016.30<0.0001
Susquehanna International Group$10,070.000.0111,223-92.04%-$116,436.23<0.0001
Legal & General$10,433.000.0111,6730%+$0<0.0001
AllianceBernstein$10,095.000.0111,2500%+$0<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.